Barclays Reiterates Overweight Rating on Radient Pharmaceuticals (RPC)
Tweet Send to a Friend
Barclays reiterated an Overweight rating and $11.00 price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
